BDR (almost) met its production target, and was smack bang in the middle of AISC guidance. I wonder why the market reaction was luke warm / slightly negative. Perhaps there was there an expectation these targets would be surpassed?
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status
